WARPTECHNEWS · LAB
HomeAIBusinessTechArchive
WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

  • Home
  • Archivio
  • Editor's Brief
  • Cerca
  • Il tuo account
  • Newsletter tech/AI

Informazioni legali

  • Privacy Policy
  • Termini di servizio
  • Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Home
Storia in 3 fonti

Glenmark gets US approval for expanded paediatric use of SAR drug

Nasal spray now approved for seasonal allergic rhinitis in patients aged 6 years and older

Raccontata dahealio.comthehindubusinessline.comeconomictimes.indiatimes.com

Confronto fonti

3 prospettive sulla stessa storia
AI · summaries
thehindubusinessline.comStai leggendo2 g fa

Glenmark gets US approval for expanded paediatric use of SAR drug

Nasal spray now approved for seasonal allergic rhinitis in patients aged 6 years and older

originale
economictimes.indiatimes.com2 g fa

Glenmark gets USFDA nod for expanded use of RYALTRIS nasal spray

Glenmark Pharmaceuticals announced US FDA approval for RYALTRIS nasal spray. This approval expands its use to children aged six to twelve years. The nasal spray treats symptoms of seasonal allergic rhinitis…

Leggi questa versione → originale
healio.com2 g fa

FDA expands Ryaltris approval to include children aged 6 to 11 years

The FDA approved Ryaltris nasal spray for treating seasonal allergic rhinitis symptoms in children aged 6 years to less than 12 years, meaning it is now approved for patients aged 6 years and older, according to a press…

Leggi questa versione → originale

Timeline cronologica

  1. martedì 21 luglio 2026·healio.com

    FDA expands Ryaltris approval to include children aged 6 to 11 years

    The FDA approved Ryaltris nasal spray for treating seasonal allergic rhinitis symptoms in children aged 6 years to less than 12 years, meaning it is now approved for patients aged…

  2. martedì 21 luglio 2026·thehindubusinessline.com

    Glenmark gets US approval for expanded paediatric use of SAR drug

    Nasal spray now approved for seasonal allergic rhinitis in patients aged 6 years and older

  3. martedì 21 luglio 2026·economictimes.indiatimes.com

    Glenmark gets USFDA nod for expanded use of RYALTRIS nasal spray

    Glenmark Pharmaceuticals announced US FDA approval for RYALTRIS nasal spray. This approval expands its use to children aged six to twelve years. The nasal spray treats symptoms…